Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > NDA - ANDA
View:
Post by Solid1 on Feb 23, 2023 10:06am

NDA - ANDA

Pidduck is talking about two approval processes here ? 
Or am I misunderstanding something ? 

David Pidduck
Yes. We thought it was important to update investors on some of the work that we've done. I think, MediPharm is probably a global leader in the characterization of pharmaceutical CBD. And with that, and with our Drug Establishment License, and with our drug master file with the U.S. FDA, it gives us an opportunity to supply API to pharmaceutical companies. So in Q3, we provided API for new novel drug applications, which are very long by nature, as well as abbreviated new drug application. And abbreviated new drug application is basically a generic application.
So our pharmaceutical partner is targeting current pharmaceutical drugs with cannabinoids and API, and they're filing a generic for that. We are being a little bit restrictive in some of the information that we're doing. There's a competitive advantage of not fully disclosing as our pharmaceutical partner would prefer that we don't get into too much detail. But as the file makes its way through the process, we will be able to continue to update all of our stakeholders.
Comment by AADADuato on Feb 23, 2023 2:40pm
Here's the current list of CBD based trials that I could find.  The joint arthritis one stands out to me as I've found labs CBD formula illuminates my knee arthritis/ joint pains I get every once in a while.  Current CBD Clinical Trials The following CBD trials are the most up to date known to ClinicalTrials.gov. If you would like to showcase a clinical study on ...more  
Comment by Solid1 on Feb 23, 2023 2:59pm
I am concerned with exactly this sentence So in Q3, we provided API for new novel drug applications New Drug Applications - NDA 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities